目的 探讨舒肝颗粒联合熊去氧胆酸胶囊治疗非酒精性脂肪肝的临床疗效。方法 选取2017年1月-2017年12月于成都市公共卫生临床医疗中心确诊并接受治疗的158例非酒精性脂肪肝患者作为研究对象，所有患者随机分为对照组和治疗组，每组各79例。对照组患者口服熊去氧胆酸胶囊，2粒/次，3次/d。治疗组在对照组治疗的基础上口服舒肝颗粒，1袋/次，2次/d。两组患者连续治疗3个月。观察两组的临床疗效，比较两组的肝功能指标、血脂指标。结果 治疗后，对照组和治疗组的总有效率分别为88.61%、96.20%，两组比较差异有统计学意义（P<0.05）。两组患者丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转氨酶（AST）、γ-谷氨酰转肽酶（γ-GT）水平均显著下降，与治疗前相比，差异具有统计学意义（P<0.05）；而治疗后与对照组相比，治疗组患者的ALT、AST、γ-GT水平均明显低于对照组，组间差异显著（P<0.05）。治疗后，两组患者的低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、三酰甘油（TG）水平均明显下降，高密度脂蛋白胆固醇（HDL-C）水平则明显上升，组内差异显著（P<0.05），而与治疗后的对照组相比，治疗组患者的HDL-C、LDL-C、TC、TG水平明显优于对照组，组间差异显著（P<0.05）。结论 舒肝颗粒联合熊去氧胆酸胶囊治疗非酒精性脂肪肝具有较好的临床疗效，可改善患者的肝功能和血脂水平，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Shugan Granules combined with Ursodeoxycholic Acid Capsules in treatment of non-alcoholic fatty liver. Methods Patients (158 cases) with non-alcoholic fatty liver in Chengdu Public Health Clinical Medical Center from January 2017 to December 2017 were randomly divided into control and treatment groups, and each group had 79 cases. Patients in the control group were po administered with Ursodeoxycholic Acid Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Shugan Granules on the basis of the control group, 1 bag/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and liver function indexes and blood lipid indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 88.61% and 96.20%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of ALT, AST, and γ-GT in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the liver function indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of LDL-C, TC, and TG in two groups were significantly decreased, but the levels of HDL-C, TC, and TG in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood lipid indexes levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shugan Granules combined with Ursodeoxycholic Acid Capsules has clinical curative effect in nonalcoholic fatty liver, can improve liver function and blood lipid levels in patient, with good safety, which has a certain clinical application value.

R978.7